Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 3Paresthesia 2Neurotoxicity Syndromes 2Neoplasm Metastasis 2

Interventions

Oxaliplatin 6Sodium Chloride 3Leucovorin 3Fluorouracil 3xaliproden 2Magnesium Sulfate 2Folfox protocol 2Calcium Gluconate 2neurotropin 1Pharmacogenomic Testing 1Gene Expression Profiling 1Capecitabine 1Bevacizumab 1Acupuncture Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurotoxicity Syndromes × xaliproden × Gastrointestinal × Clear all
NCT00305188 2016-05-04

Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.

Sanofi

Phase 3 Completed
879 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

NCT00272051 2006-09-13

XENOX - Evaluation of the Efficacy of Xaliproden in Reducing the Neurotoxicity of the Oxaliplatin + 5-FU/LV Chemotherapy

Sanofi

Phase 3 Completed
620 enrolled
Gastrointestinal

Neoplasm Metastasis, Paresthesia, Colorectal Neoplasms, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡